Jeff Yass’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Jeff Yass’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-35,500	Closed	-$93K	–	14437
2021 Q4	$93K	Buy	35,500 +2,700	+8%	+$8.16K	﹤0.01%	12197
2021 Q3	$102K	Buy	+32,800	New	+$109K	﹤0.01%	12065
2021 Q2	–	Sell	-47,300	Closed	-$164K	–	13548
2021 Q1	$164K	Buy	+47,300	New	+$192K	﹤0.01%	11582
2020 Q3	–	Sell	-13,300	Closed	-$61K	–	11366
2020 Q2	$61K	Buy	+13,300	New	+$58.9K	﹤0.01%	9698

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Jeff Yass's PHAS Position: Q1 2022 in Review

Jeff Yass sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2022, closing a stake of 273,100 shares — an estimated $443K sold.

Jeff Yass first reported a position in PHAS in Q1 2019 and held it in 8 quarters. The position peaked at $713K in Q4 2021. 56 funds tracked by Wall St. Rank hold PHAS as of Q1 2022.

Jeff Yass reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Jeff Yass sold 273,100 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $443K.
Jeff Yass first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 8 quarters.
Jeff Yass's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $713K in Q4 2021.
56 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Susquehanna International Group's 13F filing for Q1 2022, filed 16 May 2022.